Stevanato Group as unveiled its latest release of its patented on-body drug delivery system, Vertiva. The device is designed with the ability to switch between basal and bolus injections and is suitable for a wide range of subcutaneous therapies1.
Vertiva’s unique design consists of a single-use pod with a pre-filled and pre-loaded 3mL ISO cartridge, and a multi-use controller, offering potential sustainability and affordability benefits. The device can adapt to different delivery profiles and can enable the administration of small-molecule drugs and biologics.
“The Vertiva on-body delivery system supports pharma companies in increasing the accessibility of in-home care and administered treatment options, which can ultimately lead to an improved patient experience,” said Steven Kaufman, VP for drug delivery systems at Stevanato Group.